Latest Conference Articles

Peter K. Kaiser, MD, shares a promising outlook for patients with dry age-related macular degeneration, with innovative therapies in development that have the potential not only to prevent vision loss but also improve visual acuity.

A new study focuses on the specific visual field conditions and defects that can result in an increased risk of vehicular accidents, particularly in the aging population.

Compared with other medical specialties, ophthalmologists typically experience lower burnout rates, explains Peter J. McDonnell, MD.

Ophthalmology experiences lower burnout rates than other medical specialties, but some may consider the exploration of alternative paths to maintain their professional fulfillment, explains Peter J. McDonnell, MD.

Ophthalmology experiences lower burnout rates compared with other medical fields, but the profession is not immune to the issue, explains Peter J. McDonnell, MD.

Daniel H. Chang, MD, shared highlights of his presentation on a first-in-human clinical feasibility study of a dual-optic accommodating IOL system.

Analysis showed low-dose, preservative-free formulation of atropine is effective in slowing progression in children aged 3 to 17, living in the US and European Union.

Ab-interno implantation of a supraciliary allograft bio-tissue successfully reduced intraocular pressure (IOP) with comparable safety to other minimally invasive glaucoma surgical (MIGS) procedures

Investigators found that ab-interno implantation of a supraciliary allograft bio-tissue successfully reduced intraocular pressure with comparable safety to other minimally invasive glaucoma surgical procedures

The company announced updated data from the OPTIC extension study of patients diagnosed with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco. Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden.

The company presented topline Phase I/II first-in-human results at the 127th American Academy of Ophthalmology annual meeting in San Francisco, demonstrating significant improvement in visual field, in concordance with trended improvements in visual acuity and functional vision.

At the 127th American Academy of Ophthalmology annual meeting in San Francisco, Alcon revealed the full U.S. commercial availability of its cloud-based cataract planner, building on its leading image-guided clinic to OR connectivity.

According to the study, detailed in presentations at the American Academy of Ophthalmology’s annual meeting in San Francisco, pegcetacoplan injection reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study.

RxSight Inc announced educational opportunities and product updates at the American Academy of Ophthalmology's 127th Annual Meeting in San Francisco, California.

At this year's American Academy of Ophthalmology meeting, Mary Elizabeth Hartnett, MD, of the Byers Eye Institute at Stanford University presented on gender disparities in vision loss and blindness.

In a conversation with Ophthalmology Times, Mary Elizabeth Hartnett, MD, FACS, discussed her AAO presentation, focusing on the impact of blindness and vision loss on women in the United States

According to data presented at the American Academy of Ophthalmology annual meeting in San Francisco, a study of children with cell disease finds 1 in 3 had retinopathy.

Mary Elizabeth Hartnett, MD, FACS, discussed the impact of blindness and vision loss on women in the United States.

Edward J. Holland, MD, and Professor Shigeru Kinoshita, MD, discuss how a single donor cornea could potentially help over a thousand patients.

Results showed that IZERVAY met the primary objective of reducing the rate of geographic atrophy (GA) growth in patients treated monthly compared to sham-treated patients

David Hutton of Ophthalmology Times spent time with Esen K Akpek, MD, who discussed her presentation at this year's American Academy of Ophthalmology meeting.

Esen K. Akpek, MD, discussed her presentation at this year's American Academy of Ophthalmology meeting, covering recent advancements in artificial corneas

Investigators sought to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA

The ESCRS Symposium focused on innovations in the digital cataract and refractive surgery space

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their OTT166 eye drop treatment.

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.

Researchers are addressing growing concern over vision loss in people taking semaglutideat the American Academy of Ophthalmology annual meeting in San Francisco.